Download Image
    
Share
  
Post
LSALT peptide for COVID-19
1 study with 61 patients
Hospital Icon Control
Hospital Icon LSALT peptide Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 LSALT peptide studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -407% Mortality -407% Hospitalization -7% RCTs -407% Late -407% FavorsLSALT peptide Favorscontrol
May 18
2024
 Fowler et al., NCT04330690 A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
Estimated 580 patient LSALT peptide late treatment RCT with results not reported over 1.5 years after estimated completion.
Mar 15
2024
 Somayaji et al., BMJ Open, doi:10.1136/bmjopen-2023-076142 Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)
407% higher mortality (p=0.24) and 7% longer hospitalization (p=0.65). RCT 61 hospitalised moderate/severe COVID-19 patients showing no significant difference in clinical outcomes with intravenous LSALT peptide treatment.